Modella AI vs Paige
Two computational pathology companies at different points on the regulatory map. Paige produced the first authorised AI based digital pathology product, obtained through the De Novo route, which created the category and remains the reference point for what a reviewed pathology algorithm looks like. Modella builds generative and agentic tooling, including a co pilot pairing pathology foundation models with conversational interaction, which reaches tasks nobody wrote a specific algorithm for. These are not substitutes and should not be compared as such. A laboratory signing out cancer diagnoses needs the authorised detector. A research group or an academic department exploring what foundation models can do with a slide archive wants the co pilot, and should be clear with itself that using it to inform a diagnosis is a decision the laboratory is making, not one a regulator has reviewed.
- It builds generative and agentic tools for pathology, including a co pilot combining pathology foundation models with conversational interaction, which is a different layer from detection algorithms.
- Foundation models pretrained on pathology give it a route to tasks nobody wrote a specific algorithm for, which is where the field is heading.
- For a research or academic pathology department, a general purpose reasoning layer is more useful than a fixed set of cleared detectors.
- It holds the De Novo authorization that created the regulatory category for AI cancer detection support, which is the reference point everything else here is measured against.
- Authorised depth in prostate cancer detection means the capability has been reviewed rather than demonstrated.
- For a clinical laboratory signing out cases, an authorised product is a materially different proposition from a research grade co pilot.
Side by Side
| Axis | M Modella AI |
P Paige |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The regulatory positions are not comparable and should not be presented as competing claims: one holds an authorisation for a specific detection task and the other builds general purpose pathology tooling that is not a cleared diagnostic. A foundation model co pilot answering questions about a slide sits outside the framework that governs a detection algorithm, and a laboratory using it to inform a diagnosis is making that decision itself. Neither publishes pricing. Neither publishes a subgroup or site level performance analysis, and staining and scanner variation between laboratories remains the largest uncontrolled variable in both.